Common gene variants in the Tumor Necrosis Factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-hodgkin lymphoma risk

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Wang, Sophia S ^a   Purdue, Mark P ^a   Cerhan, James R ^b   Zheng, Tongzhang ^c   Menashe, Idan ^a   Armstrong, Bruce K ^d   Lan, Qing ^a   Hartge, Patricia ^a   Kricker, Anne ^e   Zhang, Yawei ^c   Morton, Lindsay M ^a   Vajdic, Claire M ^e   Holford, Theodore R ^c   Severson, Richard K ^f   Grulich, Andrew ^g   Leaderer, Brian P ^c   Davis, Scott ^h   Cozen, Wendy ⁱ   Yeager, Meredith ^a   Chanock, Stephen J ^a   Chatterjee, Nilanjan ^a   Rothman, Nathaniel ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f WAYNE STATE UNIVERSITY   (United States)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B CELL LYMPHOMA; CANCER RISK; CARCINOGENESIS; CHROMOSOME 6P; CONTROLLED STUDY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POPULATION BASED CASE CONTROL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; LYMPHOMA, NON-HODGKIN; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65449169623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005360     Document Type: Article

References (51)

1. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, et al. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 1: 27-38.
2. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, et al. (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 19: 9771-80.
3. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, et al. (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 3: 704-12.
4. Skibola CF, Nieters A, Bracci PM, Curry JD, Agana L, et al. (2008) A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 8: 4348-54.
5. Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, et al. (2007) Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 13: 4455-63.
6. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, et al. (2008) Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 11: 3161-69.
7. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 5234: 286-90.
8. Balkwill F, Coussens LM (2004) Cancer: an inflammatory link. Nature 7007: 405-6.
9. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 7007: 461-66.
10. Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 7: 2700-2707.
11. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 12: 1861-74.
12. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 6769: 503-11.
13. Rosenwald A, Staudt LM (2003) Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. pp S41-S47.
14. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, et al. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 6: 851-62.
15. Ho L, Davis RE, Conne B, Chappuis R, Berczy M, et al. (2005) MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 7: 2891-99.
16. Keller SA, Schattner EJ, Cesarman E (2000) Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 7: 2537-42.
17. DiDonato JA, Mercurio F, Karin M (1995) Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol Cell Biol 3: 1302-11.
18. Auphan N, DiDonato JA, Helmberg A, Rosette C, Karin M (1997) Immunoregulatory genes and immunosuppression by glucocorticoids. Arch Toxicol Suppl: 87-95.
19. Okamoto K, Makino S, Yoshikawa Y, Takaki A, Nagatsuka Y, et al. (2003) Identification of I kappa BL as the second major histocompatibility complex-linked susceptibility locus for rheumatoid arthritis. Am J Hum Genet 2: 303-12.
20. Whiteside TL (2007) The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 1: 25-46.
21. Altemeier WA, Zhu X, Berrington WR, Harlan JM, Liles WC (2007) Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspase-independent pathway. J Leukoc Biol 3: 721-28.
22. Rao VK, Straus SE (2006) Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 1: 15-23.
23. Mackay F, Tangye SG (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4: 347-54.
24. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, et al. (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/ BLyS and APRIL. J Immunol 5: 3268-79.
25. Mackay F, Cancro MP (2006) Travelling with the BAFF/BLyS family: are we there yet? Semin Immunol 5: 261-62.
26. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, et al. (2008) Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 2: 406-13.
27. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, et al. (2007) The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 2: 460-470.
28. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, et al. (2006) Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 6: 983-87.
29. Fillatreau S, Radbruch A (2006) IRF4 - a factor for class switching and antibody secretion. Nat Immunol 7: 704-6.
30. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, et al. (2007) A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 3: 280-292.
31. Lossos IS (2007) The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression. Cancer Cell 3: 189-91.
32. Jardin F, Ruminy P, Bastard C, Tilly H (2007) The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol 1: 73-83.
33. Ponzoni M, Arrigoni G, Doglioni C (2007) New transcription factors in diagnostic hematopathology. Adv Anat Pathol 1: 25-35.
34. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, et al. (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 10: 1204-10.
35. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, et al. (2008) IRF4 addiction in multiple myeloma. Nature 7201: 226-31.
36. Schmidt M, Hochhaus A, Konig-Merediz SA, Brendel C, Proba J, et al. (2000) Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J Clin Oncol 19: 3331-38.
37. Chatterjee N, Hartge P, Cerhan JR, Cozen W, Davis S, et al. (2004) Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 9: 1415-21.
38. Lan Q, Zheng T, Rothman N, Zhang Y, wang ss, et al. (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 10: 4101-8.
39. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, et al. (2004) Hair-coloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol 2: 148-54.
40. Hughes AM, Armstrong BK, Vajdic CM, Turner J, Grulich A, et al. (2004) Pigmentary characteristics, sun sensitivity and non-Hodgkin lymphoma. Int J Cancer 3: 429.
41. Kleihues P, Sobin LH (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press. 352 p.
42. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, et al. (2007) Proposed classification of lymphoid neoplasms for epidemiologic research from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2: 695-708.
43. Garcia-Closas M, Egan KM, Abruzzo J, Newcomb PA, Titus-Ernstoff L, et al. (2001) Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 6: 687-96.
44. Bhatti P, Sigurdson AJ, Wang SS, Chen J, Rothman N, et al. (2005) Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 10: 2449-53.
45. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, et al. (2006) SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucl Acids Res Suppl 1: D617-D621.
46. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 1: 106-20.
47. Taylor J, Tibshirani R (2006) A tail strength measure for assessing the overall univariate significance in a dataset. Biostat 2: 167-81.
48. Westfall P, Zaykin D, Young S (2002) Multiple tests for genetic effects in association studies. Methods Mol Biol. pp 143-68.
49. Chen B, Sakoda L, Hsing AW, Rosenberg PS (2006) Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genet Epidemiol 6: 495-507.
50. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 1: 289-300.
51. Barrett J, Fry B, Maller J, Daly M (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2: 263-65.